Cargando...
Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/− binimetinib or alpelisib
BACKGROUND: Treatment strategies inhibiting BRAF in combination with EGFR have been developed in patients with BRAF(V600E) mutant metastatic colorectal cancer, but intrinsic and secondary resistance remains a challenge. We aimed to investigate which genetic alterations cause intrinsic non-response a...
Gardado en:
| Publicado en: | Br J Cancer |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Nature Publishing Group UK
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7782586/ https://ncbi.nlm.nih.gov/pubmed/33204026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01147-2 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|